Jupiter Wellness, Inc. - JUPW STOCK NEWS

Jupiter Wellness (NASDAQ:JUPW) announced a significant milestone regarding its eczema treatment, JW-100, by receiving a written response from the FDA following a Type B pre-IND meeting. This feedback supports Jupiter's development plan, aiding in the IND filing for JW-100 clinical studies. The drug cleared or reduced eczema symptoms in a recent study, suggesting its potential superiority over current treatments. With the global eczema market valued at $10 billion and projected to grow at a CAGR of 13% from 2020-2025, Jupiter Wellness is poised for future success.

Jupiter Wellness (NASDAQ:JUPW) has filed a registration statement with the SEC to sponsor Jupiter Wellness Acquisition Corp., a SPAC targeting AI in medicine, aiming to raise $100 million. The initiative is aligned with the growing healthcare AI market, projected to reach $36 billion by 2025. Jupiter has assembled a board with extensive healthcare and financial experience, targeting investments in AI-driven therapeutics with enterprise values between $300 million and $1 billion. The FDA's new clearance process supports rapid AI technology adoption, enhancing medical diagnostics and reducing care costs.

Jupiter Wellness (NASDAQ:JUPW) announced the enrollment of its first patient in a double-blinded, placebo-controlled trial for its cannabinoid receptor agonist aimed at treating first-degree burns. The study will involve 50 patients with superficial partial thickness burns covering 10% or less of their body. The primary endpoint is the time to full wound healing. Jupiter aims to expand its skincare product line, including CaniSun™ and Photocil™. The burn care market, valued at $2.1 billion in 2020, is projected to grow at a CAGR of 7% through 2028.

Jupiter Wellness (NASDAQ:JUPW) has announced significant developments in its clinical and commercial initiatives. Notably, the launch of Photocil™, an OTC drug for psoriasis and vitiligo, is expected in Q1 2022, with FDA approval numbers assigned. Additionally, the company submitted a pre-IND package for JW-100 for atopic dermatitis and anticipates a meeting with the FDA in Q4 2021. A Phase III study comparing JW-100 to Eucrisa for eczema is set to begin recruiting by Q4 2021, while enrollment for studies on actinic keratosis and burns is also underway.

Jupiter Wellness, Inc. (NASDAQ:JUPW) has extended its endorsement agreement with golfing legend Ernie Els for two additional years. Els will promote the CaniSun Suncare Product Line, which features CBD-infused sunscreens targeted at both elite athletes and everyday users. CEO Brian John praised Els for his global appeal and reputation. Els expressed his commitment to CaniSun, citing its effectiveness for sun protection during his frequent outdoor activities. Jupiter Wellness continues to focus on the endocannabinoid system for its skincare therapeutics, addressing issues like eczema and skin cancer.

Jupiter Wellness, Inc. (NASDAQ:JUPW) has submitted a pre-IND meeting request to the FDA for its JW-100 drug, aimed at treating mild to moderate eczema. This meeting aims to gain early FDA feedback on the drug development strategy, potentially accelerating the process. The eczema treatment market is valued at $10 billion and expected to grow at 13% CAGR from 2020-2025. Clinical trials indicate that JW-100 has significantly improved eczema symptoms in 50% of adult patients after two weeks. Jupiter also produces a range of skincare products generating revenue.

Jupiter Wellness (NASDAQ:JUPW) is moving forward with its clinical program for JW-100, targeting the treatment of mild to moderate eczema. On August 16, 2021, the company announced it has requested an IND number from the US FDA for a pre-IND submission regarding preclinical and clinical studies. A recent double-blinded placebo-controlled trial showed JW-100 significantly reduced ISGA scores in 50% of patients after just two weeks. The development is supported by expertise from Applied Biology Inc. and aims for FDA approval to provide effective eczema relief.

Jupiter Wellness, Inc. (NASDAQ:JUPW) successfully completed a $32.5 million follow-on offering of common stock and warrants, with Aegis Capital Corp. serving as the sole bookrunner. This funding is intended to enhance the company’s pipeline of skin care therapeutics targeting conditions such as eczema and skin cancer. Jupiter is recognized for its innovative over-the-counter skincare products, including the CaniSun™ sunscreen. The offering aims to bolster the company's growth in the expanding skincare market.

Jupiter Wellness (NASDAQ:JUPW) announced the closing of a $32.5 million underwritten public offering on July 26, 2021. The offering included 11,066,258 shares of common stock and 11,607,142 warrants at a public price of $2.79 per share. The warrants are exercisable immediately at the same price and expire in five years. The offering's proceeds will enhance liquidity and fund the company's expanding line of skin care therapeutics, which target conditions like eczema and skin cancer. Aegis Capital Corp. managed the offering.